Şunu aradınız:: times baseline (İngilizce - Maltaca)

baseline
linja bażi

time from baseline in months
Ħin mil-linja bażi f’xhur

alanine aminotransferase increased (sgpt > 5 times baseline) × Λ * °
alanine aminotransferase miżjud (sgpt > 5 darbiet il- linja bażi ta ’ referenza) ×Λ * °

alanine aminotransferase increased (sgpt> 5 times baseline)   * °
alanine aminotransferase miżjud (sgpt> 5 darbiet il-linja bażi)   * °

monitor transaminases weekly until return to <3 times uln or baseline.
issorvelja it-transaminases kull ġimgħa sakemm jirritornaw għal < 3 darbiet uln jew għal-linja bażi.

daily on time (h) baseline
Ħin on kuljum (siegħat) linja bażi

proportion of daily on time (%) baseline
proporzjon ta ’ Ħin on kuljum (%) linja bażi

albumin levels 3 times baseline in 10% and platelets < 50,000/mm3 in 20%.
livelli ta’ albumina ta’ 3 darbiet il-linja bażi f’10% u plejtlits < 50,000/mm3 f’20%.

equal to 2 times baseline, viraferon therapy may be continued unless signs and symptoms of liver failure are observed.
jekk matul it- terapija b’ viraferon l- alt jogħla f’ daqqa u jilħaq jew jaqbeż id- doppju tal- livelli bażi, it- terapija b’ viraferon tista ’ titkompla sakemm ma jkunux innutati sinjali u sintomi ta ’ indebolimet qawwi tal- fwied.

after this time, triglyceride levels reverted back to baseline.
wara dan iż-żmien, il-livelli tat- trigliċeridi reġgħu lura għal-linja bażi.

improvement from baseline in haq averaged over time from week 30 to week 54
titjib mil-linja bażi fl-haq li nkiseb bħala medja meħuda maż-żmien minn

in this study, only one patient had lvh at baseline and remained stable over time.
f’dan l-istudju, pazjent wieħed biss kellu lvh fil-linja bażi u baqa’ stabbli maż-żmien.

figure 5 mean change from baseline bcva over time to month 12 (radiance)
figura 5 il-bidla medja mil-linjabażi ta’ bcva matul iż-żmien sat-12-il xahar (radiance)

a mean peak aptt prolongation of around 1.4 times baseline value is observed following a subcutaneous (sc) b.i.d. injection of 15mg desirudin.
l-ogħla livell medju ta’ aptt imtawwal kien ta’ madwar 1.4 drabi tal-valur fil-bidu, wara injezzjoni subkutanja (sc) b.i.d. ta’ 15 mg desirudin.

figure 2 mean change in visual acuity from baseline over time in study d2301 (restore)
figura 2 bidla medja fl-akutezza tal-vista mil-linja bażi maż-żmien, fl-istudju d2301 (restore)

platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued.
l- aggregazzjoni tal-plejtlets u l-ħin ta’ emorraġija reġgħu marru bil-mod għall-valuri tal-linja bażi, ġeneralment fi żmien 5 ijiem wara li kienet twaqqfet il-kura.

albumin levels 3 times baseline in 2%, lipase levels > 3 times baseline in 11% and platelets < 50,000/mm3 in < 1%.
livelli ta’ albumina ta’ 3 darbiet tal-linja bażi fi 2% , livelli ta’ lipase ta’ > 3 darbiet tal-linja bażi fi 11% u plejtlits ta’ < 50,000/mm3 f’< 1%.

albumin levels 3 times basel ine in 2%, lipase levels > 3 times baseline in 11% and platelets < 50,000/mm3 in < 1%.
38 livelli ta ’ l- albumina ta ’ 3 darbiet iktar mil - linja bażi fi 2%, livelli ta ’ lipase > 3 drabi l- linja bażi fi 11% u platelets < 50, 000/ mm3 fi < 1%.

in studies with lamivudine-refractory patients, on treatment alt elevations > 10 times uln and > 2 times baseline occurred in 2% of entecavir treated patients vs 11% of lamivudine treated patients.
fi studji fuq pazjenti refrattarji għal lamivudine, seħħew żjidiet fil-livelli ta’ alt waqt it-trattament ta’ > 10 darbiet l-uln u > darbtejn il- linja bażi fi 2% tal-pazjenti trattati b’entecavir meta mqabbla ma’ 11% tal-pazjenti trattati b’lamivudine.

amylase levels > 3 times baseline occurred in 2% of patients, lipase levels > 3 times baseline in 18% and platelets < 50,000/ mm3 in < 1%.
livelli ta ’ amylase > 3 darbiet il- linja bażi fi 2% tal- pazjenti, livelli ta ’ lipase > 3 darbiet il- linja bażi fi 18% u platelets < 50, 000/ mm3 f ’ < 1%.